#anti-obesity-drugs

[ follow ]
#lasker-awards

Obesity-Drug Pioneers Win Prestigious Lasker Award for Medical Science

The development of anti-obesity drugs is being recognized with prestigious awards, signaling a significant medical advancement.
GLP-1 mimetic drugs that help control appetite are gaining attention in the healthcare landscape.

Obesity-drug pioneers win prestigious Lasker Award for medical science

Recognition of GLP-1 research marks a significant breakthrough in anti-obesity therapies, potentially paving the way for future Nobel Prize considerations.

Obesity-Drug Pioneers Win Prestigious Lasker Award for Medical Science

The development of anti-obesity drugs is being recognized with prestigious awards, signaling a significant medical advancement.
GLP-1 mimetic drugs that help control appetite are gaining attention in the healthcare landscape.

Obesity-drug pioneers win prestigious Lasker Award for medical science

Recognition of GLP-1 research marks a significant breakthrough in anti-obesity therapies, potentially paving the way for future Nobel Prize considerations.
morelasker-awards
#anti-obesity drugs

Black patients have less access to anti-obesity drugs, data shows

Health disparities exist in the distribution of anti-obesity and diabetes drugs.
White people are four times more likely to receive a prescription than Black people.
Affordability and lack of access to medical care contribute to the unequal distribution.

Doctors grapple with patients' demand for weight-loss drugs

Primary care doctors are facing an influx of requests for anti-obesity drugs, including from patients who may not necessarily need them.
The demand for GLP-1 agonist drugs, such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound, is expected to increase after new data shows their potential in reducing heart problems.
There is a need for balanced consideration of other treatments and interventions before resorting to these drugs, as not everyone may require them.

Black patients have less access to anti-obesity drugs, data shows

Health disparities exist in the distribution of anti-obesity and diabetes drugs.
White people are four times more likely to receive a prescription than Black people.
Affordability and lack of access to medical care contribute to the unequal distribution.

Doctors grapple with patients' demand for weight-loss drugs

Primary care doctors are facing an influx of requests for anti-obesity drugs, including from patients who may not necessarily need them.
The demand for GLP-1 agonist drugs, such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound, is expected to increase after new data shows their potential in reducing heart problems.
There is a need for balanced consideration of other treatments and interventions before resorting to these drugs, as not everyone may require them.
moreanti-obesity drugs

Tracking Ozempic's Nausea Side Effect to Specific Neurons May Lead to Better Drugs

Scientists pinpointed a brain pathway involved in nausea from anti-obesity drugs, aiming to develop weight-loss drugs with fewer side effects.

Daily briefing: The mystery man at the centre of the Human Genome Project

One man was central to the first human genome sequence, anti-obesity drugs cause nausea through specific brain circuits, midsize black hole possibly in the Galaxy.
[ Load more ]